natgillin/translations-raw huggingface dataset:
absence of menstruation, excessive menses flu-like illness, increased weight, infusion-related reactions
izostanak menstruacije, preobilne menstruacije bolest nalik gripi, povećanje tjelesne težine, reakcije vezane uz infuziju
absence of prior virologic failure
izostanak prethodnog virološkog neuspjeha
absence of safety data on the endometrium for continuous treatment longer than 3 months.
odsutnost podataka o sigurnosti kontinuiranog liječenja duljeg od 3 mjeseca za endometrij.
Absence of t(4;14)
Odsutnost t(4;14)
absent or heavy menstrual periods
izostanak ili obilne menstruacije
absent or heavy menstrual periods,
izostanak ili obilne menstruacije
Absent Present
Prisutno
Absent Slight Moderate
nema blagi umjereni
Absolute % predicted
Procijenjeni apsolutni
Absolute bioavailability
Apsolutna bioraspoloživost
Absolute bioavailability after a 3 mg dose is about 36%13%.
Apsolutna bioraspoloživost nakon doze od 3 mg iznosi oko 36%±13%.
Absolute bioavailability has been estimated to be between 64 and 80 %.
Apsolutna bioraspoloživost je procijenjena na između 64 i 80%.
Absolute bioavailability in 12 healthy adults following single-dose administration was 93  9 % (mean SD) for a 50 mg tablet and 91  8% for an oral solution.
Apsolutna bioraspoloživost u 12 zdravih odraslih osoba nakon jednokratne doze bila je 93 ± 9% (srednja vrijednost SD) za tabletu od 50 mgi 91 ± 8% za oralnu otopinu.
Absolute bioavailability in fasted condition (n = 8) was 2.9% (90% CI = 2.1 – 3.9) and doubled when combined with a meal.
Apsolutna bioraspoloživost natašte (n = 8) bila je 2,9% (90% CI = 2,1 – 3,9), a udvostručila se kada je kombiniran s obrokom.
Absolute bioavailability is high (95%), showing that safinamide is almost completely absorbed after oral administration and first pass metabolism is negligible.
Apsolutna bioraspoloživost je visoka (95%) pokazujući tako da se safinamid gotovo u potpunosti apsorbira nakon peroralne primjene i metabolizam prvog prolaza je zanemariv.
Absolute bioavailability of a 0.30 mg/kg subcutaneous dose versus a 0.30 mg/kg intravenous dose is 82 %.
Apsolutna bioraspoloživost supkutane doze od 0,30 mg/kg u odnosu na intravensku dozu od 0,30 mg/kg iznosi 82%.
Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60 % in healthy subjects.
Apsolutna bioraspoloživost tablete metformina u dozi od 500 mg u zdravih ispitanika bila je približno 50-60%.
Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects.
Apsolutna bioraspoloživost tablete metformina od 500 mg približno je 50-60% u zdravih ispitanika.
Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects.
Apsolutna bioraspoloživost tablete metformina od 500 mg u zdravih ispitanika iznosi oko 50-60%.
Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects.
Apsolutna bioraspoloživost tablete od 500 mg metformina je približno 50-60% u zdravih ispitanika.
Absolute bioavailability of a 500 mg or 850 mg metformin tablet is approximately 50-60% in healthy subjects.
Apsolutna bioraspoloživost tablete metformina od 500 mg ili 850 mg iznosi približno 50-60% u zdravih osoba.
Absolute change from baseline in percent
Apsolutna promjena u postotku predviđenog FEV1 od početne vrijednosti (postotni bodovi)
Absolute change from baseline in percent predicted FEV1 (percentage points)
Apsolutna promjena u postotku predviđenog FEV1 od početne vrijednosti (postotni bodovi)
Absolute change in BMI at
Apsolutna promjena indeksa tjelesne mase u
Absolute Change in Haemoglobin Level (g/dL)
Apsolutna promjena u razini hemoglobina (g/dl)
Absolute Change in Haemoglobin Level (g/dL) (secondary endpoint)
Apsolutna promjena u razini hemoglobina (g/dl) (sekundarni ishod)
Absolute change in percent predicted FEV1
Apsolutna promjena u postotku predviđenog FEV1
Absolute change in ppFEV1 at
Apsolutna promjena ppFEV1 u 24. tjednu (postotni bodovi)
Absolute difference in number per year vs VI (95% CI)
Apsolutna razlika u godišnjem broju naspram VI (95% CI)
absolute lymphocyte count
apsolutni broj limfocita
Absolute lymphocyte count <0.2x109/l, if confirmed, should lead to treatment interruption until recovery, because in clinical studies, fingolimod treatment was interrupted in patients with absolute lymphocyte count <0.2x109/l.
Ako se utvrdi apsolutni broj limfocita <0,2x109/l, terapiju je potrebno prekinuti do oporavka, budući da je i u kliničkim ispitivanjima terapija fingolimodom bila prekinuta u bolesnika s apsolutnim brojem limfocita <0,2x109/l.
Absolute neutrophil count (ANC)  1,500/mm3
apsolutni broj neutrofila (ABN)  1500/mm3
absolute neutrophil count < 1500/mm³ platelet count < 100000/mm³
apsolutni broj neutrofila < 1500/mm³ broj trombocita < 100 000/mm³
Absolute neutrophil count >1500/microlitre
Apsolutni broj neutrofila > 1500/mikrolitra
Absolute neutrophil count decreased (<1,500/mm³) 
Smanjeni apsolutni broj neutrofila (< 1500/mm3) x
Absolute neutrophil count decreased (<1,500/mm³) 
Smanjeni apsolutni broj neutrofila (< 1500/mm³)  
Absolute neutrophil count decreased (<1500/mm³) 
Smanjeni apsolutni broj neutrofila (<1500/mm³) 
absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
smanjen apsolutni broj neutrofila, povišena alkalna fosfataza, sniženi albumini u krvi, povišena amilaza u krvi, povišen bilirubin u krvi, povišen kolesterol u krvi, povišen kreatinin u krvi, povišene vrijednosti glukoze u krvi, povišene vrijednosti dušika iz ureje u krvi, povišene vrijednosti kreatin fosfokinaze, povišene vrijednosti glukoze natašte, glukoza u urinu, povišene vrijednosti lipoproteina visoke gustoće, povećan međunarodni normalizirani omjer (INR), povišene vrijednosti lipoproteina niske gustoće, smanjen broj trombocita, eritrociti u urinu, povećan opseg struka, porast tjelesne težine, smanjen broj bijelih krvnih stanica
absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
smanjen apsolutni broj neutrofila, povišena alkalna fosfataza, sniženi albumini u krvi, povišena amilaza u krvi, povišen bilirubin u krvi, povišen kolesterol u krvi, povišen kreatinin u krvi, povišene vrijednosti glukoze u krvi, povišene vrijednosti dušika iz ureje u krvi, povišene vrijednosti kreatin fosfokinaze, povišene vrijednosti glukoze natašte, glukoza u urinu, povišeni lipoproteini visoke gustoće, povećan međunarodni normalizirani omjer (INR), povišeni lipoproteini niske gustoće, smanjen broj trombocita, eritrociti u urinu, povećan opseg struka, porast tjelesne težine, smanjen broj bijelih krvnih stanica
Absolute oral bioavailability is estimated to be 72%.
Procjenjuje se da je apsolutna oralna bioraspoloživost 72%.
Absolute oral bioavailability relative to intravenous administration has not been determined
Apsolutna bioraspoloživost peroralno primjenjenog lijeka u odnosu na intravenoznu primjenu nije ustanovljena.
Absolute reduction in fracture event rate % (CI)
Apsolutno smanjenje stope događaja za prijelome % (CI)
Absolute reduction in fracture event rate % (CI)
Apsolutno smanjenje stope događaja za prijelome (%)
Absolute Risk Reduction
Smanjenje apsolutnog rizika
Absorbed dose per unit radioactivity administered (mSv/MBq)
Apsorbirana doza po jedinici primijenjene radioaktivnosti (mSv/MBq)
Absorbed oseltamivir is primarily (> 90 %) eliminated by conversion to oseltamivir carboxylate.
0 %) eliminira pretvorbom u oseltamivirkarboksilat.
Absorbed radiation dose
Apsorbirana doza zračenja
Absorption
Apsorpcija:
Absorption
Biotransformacija
Absorption
OTFC
Absorption
Sojin lecitin
Absorption : In HIV-infected adult patients, Invirase in combination with ritonavir at doses of 1000/100 mg twice daily provides saquinavir systemic exposures over a 24-hour period similar to or greater than those achieved with saquinavir soft capsules 1200 mg tid (see Table 8).
Apsorpcija: U odraslih bolesnika zaraženih HIV-om Invirase u kombinaciji s ritonavirom u dozi od 1000/100 mg dvaput na dan dovodi do sistemske izloženosti sakvinaviru tijekom 24 sata koja je slična ili veća od izloženosti postignute uz meke kapsule sakvinavira u dozi od 1200 mg triput na dan (vidjeti Tablicu 8).
Absorption and distribution:
Apsorpcija i distribucija
Absorption differences have been observed between adult and paediatric populations (see “Special populations”).
Između odrasle i pedijatrijske populacije primijećene su razlike u apsorpciji (vidjeti 'Posebne populacije').
Absorption is not limited by penetration of the drug across the intestinal barrier but is predominantly influenced by an extensive first pass effect.
Apsorpcija nije ograničena prolazom lijeka kroz intestinalnu barijeru ali je u najvećem djelu pod utjecajem prvog prolaska kroz jetru.
Absorption is variable and the mean oral bioavailability of tacrolimus (investigated with the Prograf formulation) is in the range of 20% - 25% (individual range in adult patients 6% - 43%).
Apsorpcija varira i prosječna oralna biološka raspoloživost takrolimusa (ispitana s formulacijom Prograf) kreće se u rasponu od 20% do 25% (individualni raspon u odraslih bolesnika 6% - 43%).
Absorption of both iron and antibiotic may be reduced if oral iron is given with tetracycline.
Apsorpcija željeza i antibiotika može biti smanjena ako se pripravak željeza za peroralnu primjenu daje zajedno s tetraciklinom.
Absorption of deuterated tocofersolan showed a normal pattern in lipoproteins: alpha- tocopherol peaked first in chylomicrons, then in very low- density lipoproteins (VLDL) and finally in low- density lipoproteins (LDL) and high-density lipoproteins (HDL), and the disappearance portions of the curves paralleled those in control subjects.
Apsorpcija tokofersolana obilježenog deuterijem pokazala je normalan obrazac u lipoproteinima: alfa-tokoferol prvo je postigao vršnu koncentraciju u hilomikronima, zatim u lipoproteinima vrlo niske gustoće (VLDL) te konačno u lipoproteinima niske gustoće (LDL) i lipoproteinima visoke gustoće (HDL), a završni dijelovi krivulja bili su paralelni onima kod kontrolnih ispitanika.
Absorption of Fortacin in conjunctival tissues has not been determined.
Nije utvrđeno koliko se Fortacin apsorbira u tkivu konjuktive.
Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
Apsorpcija hidroklorotiazida oslabljena je u prisutnosti smola anionskih izmjenjivača.
Absorption of tipranavir, co-administered with low dose ritonavir, is reduced in the presence of antacids (see section 4.5).
Apsorpcija tipranavira s niskom dozom ritonavira smanjena je u prisustvu antacida (vidjeti dio 4.5).
Absorption/dose proportionality: pharmacokinetics were linear up to a dose of 650 mg/m2.
Apsorpcija/proporcionalnost doze: Farmakokinetika je bila linearna do doze od 650 mg/m2.
Absorption: After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6–12 hours.
Apsorpcija: Nakon peroralne primjene terapijskih doza samo amlodipina, vršne koncentracije amlodipina u plazmi postižu se u 6–12 sati.
Absorption: Duloxetine is well absorbed after oral administration with a Cmax occurring 6 hours post dose.
Apsorpcija: duloksetin se nakon peroralne primjene dobro apsorbira, pri čemu se Cmax postiže 6 sati nakon doze.
Absorption: Duloxetine is well absorbed after oral administration with a Cmax occurring 6 hours post dose.
Apsorpcija: Duloksetin se nakon peroralne primjene dobro apsorbira, pri čemu se Cmax postiže 6 sati nakon uzimanja doze.
Absorption: Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2–4 hours.
Apsorpcija: Nakon peroralne primjene samo valsartana, vršne koncentracije valsartana u plazmi postižu se u 2–4 sata.
Absorption: Memantine has an absolute bioavailability of approximately 100%.
Apsorpcija: memantin ima apsolutnu bioraspoloživost od približno 100%.
Absorption: The absolute bioavailability of recombinant human growth hormone after subcutaneous administration is about 80%.
Apsorpcija: Apsolutna bioraspoloživost rekombinantnog humanog hormona rasta nakon supkutane primjene iznosi približno 80%.
Absorption: the absorption of maraviroc is variable with multiple peaks.
Apsorpcija: apsorpcija maraviroka je varijabilna s nekoliko vršnih vrijednosti.
Absorption: The mean absolute bioavailability of ranolazine after oral administration of immediate- release ranolazine tablets ranged from 35−50%, with large inter-individual variability.
Apsorpcija: Srednja apsolutna bioraspoloživost ranolazina nakon peroralne primjene tableta ranolazina s brzim otpuštanjem iznosila je 35−50%, uz veliku individualnu varijabilnost.
Abundance
Relativni intenzitet
Abundance (%)
Zastupljenost (%)
Abuse of benzodiazepines and benzodiazepine-like active substances has been reported.
Zabilježena je zloupotreba benzodiazepina i lijekova srodnih benzodiazepinima .
abusing or misusing the medicine
zlouporaba ili kriva upotreba lijeka
AC-052-355 was a multi-centre, randomised, double- blind, parallel-group study of bosentan versus placebo in 33 patients with severe pulmonary arterial hypertension who were receiving concomitant epoprostenol therapy.
AC-052-355 bila je multicentrična, randomizirana, dvostruko slijepa, s paralelnim grupama, studija bosentana u odnosu na placebo na 33 bolesnika s teškom plućnom arterijskom hipertenzijom koji su istodobno dobivali epoprostenol.
AC-052-355 was a multi-centre, randomised, double-blind, parallel-group study of bosentan versus placebo in 33 patients with severe pulmonary arterial hypertension who were receiving concomitant epoprostenol therapy.
AC-052-355 bila je multicentrična, randomizirana, dvostruko slijepa, s paralelnim grupama, studija bosentana u odnosu na placebo na 33 bolesnika s teškom plućnom arterijskom hipertenzijom koji su istodobno dobivali epoprostenol.
AC-052-356 was an open- label, uncontrolled study; 10 of the 19 paediatric patients were on concomitant bosentan and epoprostenol therapy during the 12-week study.
AC-052-356 bila je otvorena, nekontrolirana studija; 10 od 19 pedijatrijskih bolesnika istodobno su dobivali bosentan i epoprostenol tijekom 12 tjedana.
AC-052-356 was an open-label, uncontrolled study; 10 of the 19 paediatric patients were on concomitant bosentan and epoprostenol therapy during the 12-week study.
AC-052-356 bila je otvorena, nekontrolirana studija; 10 od 19 pedijatrijskih bolesnika istodobno su dobivali bosentan i epoprostenol tijekom 12 tjedana.
Acacia
arapska guma
Acanthosis Pruritis
akantoza pruritis
acarbose, (an anti-diabetic drug used to treat type 2 diabetes mellitus). alli is not recommended for people taking acarbose.
akarbozu (antidijabetički lijek koji se koristi za liječenje diabetes mellitusa tipa 2). alli se ne preporučuje ljudima koji uzimaju akarbozu.
Accelerated (n= 174)
(n= 387)
Accelerated and blast phase CML patients
Bolesnici s KML-om u ubrzanoj i blastičnoj fazi
Accelerated Elimination Procedure: Cholestyramine and activated charcoal
Postupak ubrzane eliminacije: kolestiramin i aktivni ugljen
Accelerated hypertension, Hypertension, Haematoma, Hot flush, Vein disorder
ubrzana hipertenzija, hipertenzija, hematomi, naleti vrućine, venski poremećaj
Accelerated Phase
Ubrzana faza
Accelerated phase (n=137)*
Ubrzana faza (n=137)
Accelerated Phase CML
Ubrzana faza KML
Accelerated phase is an intermediate phase among the chronic phase and the onset of blast crisis; it is considered as the first manifestation of resistance to therapy.
Ubrzana faza je prijelazna faza između kronične faze i početka blastične krize; smatra se prvim znakom otpornosti na liječenje.
Accelerated phase is an intermediate phase among the chronic phase and the onset of the blast crisis; it is considered as the first manifestation of resistance to therapy.
Ubrzana faza predstavlja prijelaznu fazu između kronične faze i početka blastične krize; smatra se prvom manifestacijom rezistencije na liječenje.
Accelerated phase is defined by the presence of any of the following: blasts ≥ 15% but < 30% in blood or bone marrow, blasts plus promyelocytes ≥ 30% in blood or bone marrow (providing < 30% blasts), peripheral blood basophils ≥ 20%, platelets < 100 x 109/l unrelated to therapy.
Ubrzana faza se definira prisutnošću bilo kojeg od sljedećih kriterija: blasti 15% ali <30% u krvi ili koštanoj srži, blasti plus promijelociti 30% u krvi ili koštanoj srži (što daje <30% blasta), bazofili u perifernoj krvi 20%, trombociti <100 x 109/l nevezano uz terapiju.
ACCENT I (week-2 responders)
ACCENT I (bolesnici s odgovorom u 2. tjednu)
Acceptable solvents for reconstitution of Dynastat are:
Prihvatljiva otapala za rekonstituciju Dynastata su:
Access System should include three key principles that will be incorporated within each system in all Member States.
Kontrolirani sustav pristupa mora uključivati tri ključna načela koja će se uključiti u svaki sustav u svim državama članicama.
Accidental -ingestion can be lethal for children.
Nehotično gutanje kapsula može biti smrtonosno za djecu.
Accidental administration is dangerous – see Summary of Product Characteristics before use
Slučajna primjena je opasna – vidi Sažetak opisa svojstava prije upotrebe.
Accidental contact with the skin or eyes should be treated immediately and thoroughly with copious amounts of water
u slučaju nehotičnog kontakta s kožom ili očima, potrebno ih je odmah i temeljito isprati obilnim količinama vode
Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.
Kod slučajnog kontakta s kožom ili očima potrebno je odmah ispirati obilnim količinama vode.
Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.
Pri nehotičnom doticaju s kožom ili očima, kontaktna površina mora se odmah isprati obilnom količinom vode.
Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.
Pri slučajnom kontaktu s kožom ili očima kontaktna površina mora se odmah obilno isprati vodom.
Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.
U slučaju kontakta topotekana s kožom ili očima odmah je potrebno ispiranje obilnim količinama vode.
Accidental contact with the skin, eyes or mucous membranes must be treated immediately with copious amounts of water.
Koža, oči ili sluznica koji dođu u slučajni kontakt s lijekom moraju se odmah isprati obilnim količinama vode.
Accidental exposure (including eye pain, eye and throat irritation and cough). o Frequency not known: frequency cannot be estimated from the available data
lučajna izloženost (uključujući bol oka, nadržaj oka i grla i kašalj). o nepoznata učestalost: učestalost se ne može procijeniti iz dostupnih podataka
Accidental exposure of Healthcare Professionals (HCPs) to IMLYGIC
Slučajno izlaganje zdravstvenih radnika lijeku IMLYGIC
Accidental exposure to freezing temperatures does not adversely affect the stability of Biograstim.
Slučajno izlaganje temperaturama zamrzavanja ne utječe negativno na stabilnost lijeka Biograstim.
Accidental exposure to freezing temperatures does not adversely affect the stability of Ratiograstim.
Slučajno izlaganje temperaturama zamrzavanja ne utječe negativno na stabilnost lijeka Ratiograstim.
Accidental exposure to freezing temperatures does not adversely affect the stability of Tevagrastim.
Slučajno izlaganje temperaturama zamrzavanja ne utječe negativno na stabilnost lijeka Tevagrastim.
Accidental exposure to freezing temperatures for up to 24 hours does not affect the stability of Nivestim.
Slučajno izlaganje temperaturama smrzavanja u trajanju do 24 sata ne utječu na stabilnost lijeka Nivestim.
Accidental falls
Slučajni padovi
Accidental ingestion may cause side effects.
Slučajno gutanje može izazvati nuspojave.
Accidental ingestion of the entire contents of a bottle of OPATANOL would deliver a maximum systemic exposure of 5 mg olopatadine.
Nehotičnim gutanjem cijelog sadržaja bočice OPATANOLA, organizam bi sustavno bio izložen maksimalnoj količini od 5 mg olopatadina.
accidental inhalation of food with risk of pneumonia (lung infection),
lučajno udisanje hrane uz rizik od razvoja pneumonije (upale pluća),
Accidental injection is dangerous - see package insert before use for further information and additional warnings.
Nehotično je injiciranje opasno - vidi uputu o VMP prije primjene za daljnje informacije i dodatna upozorenja.
Accidental injection is dangerous – read the package leaflet before use.
Nehotično injiciranje je opasno - pročitajte uputu o VMP prije primjene.
Accidental injection is dangerous – read the package leaflet before use.
Nehotično injiciranje je opasno – vidi uputu o VMP prije primjene.
Accidental injection is dangerous – see package insert before use.
Nehotično je injiciranje opasno - vidi uputu o VMP prije primjene.
Accidental injection is dangerous – see package leaflet before use.
Nehotično injiciranje je opasno - pogledajte uputu o VMP prije primjene.
Accidental injection is dangerous – see package leaflet before use.
Nehotično injiciranje je opasno – pogledajte uputu o VMP prije primjene.
Accidental injection is dangerous.
Slučajna primjena je opasna
Accidental injection is dangerous.
Slučajna primjena je opasna.
Accidental injection may cause severe pain and selling, particularly if injected into a joint or finger – this could result in the loss of the finger if prompt medical attention is not given.
Slučajno injiciranje može prouzročiti jaku bol i oticanje, naročito ako se cjepivo injicira u zglob ili prst, što može rezultirati gubitkom zahvaćenog prsta ako se ne pruži hitna medicinska pomoć.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – this could result in the loss of the finger if prompt medical attention is not given.
Nehotična injekcija može prouzročiti jaku bol i oticanje, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ako nije pružena hitna medicinska pomoć.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – this could result in the loss of the finger if prompt medical attention is not given.
Nehotična injekcija može prouzročiti jaku bol i otjecanje, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ukoliko nije pružena hitna medicinska pomoć.
Accidental injection may cause severe pain and swelling, particularly if injected into a joint or finger – this could result in the loss of the finger if prompt medical attention is not given.
Nehotično injektiranje može uzrokovati snažnu bol i oticanje, posebice ako se injektira u zglob ili prst - to bi moglo uzrokovati gubitak prsta ako se odmah ne pruži liječnička pomoć.
Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Nehotična injekcija/samo injicirane može prouzročiti jaku bol i otjecanje, naročito ako se injicira u zglob prsta, a u rijetkim slučajevima može rezultirati gubitkom zahvaćenog prsta ukoliko nije pružena hitna medicinska pomoć.